Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study

Aging Clin Exp Res. 2020 May;32(5):959-962. doi: 10.1007/s40520-019-01436-8. Epub 2019 Dec 14.

Abstract

Hip fractures are the most common osteoporotic fractures related to disability in older adults, requiring surgery and a subsequent rehabilitation treatment. Sarcopenia is currently considered as a predictive of worse outcome in hip fracture patients and myostatin has been recently proposed a potential biomarker of this condition. Twenty hip fracture patients after total hip replacement (mean aged 75.9 ± 2.4 years) were randomly divided into two groups of ten subjects (groups A and B). Both groups performed a rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol). Group A received also 2-month amino acid supplementation. Serum myostatin levels significantly decreased after 2 months in both group A (p = 0.01) and group B (p = 0.03) in sarcopenic patients only in group A (p = 0.04). These results suggest that myostatin might be considered a promising biomarker of sarcopenia in hip fracture older adults' patients undergoing rehabilitation and amino acid supplementation.

Keywords: Amino acids; Hip fractures; Myostatin; Nutrition therapy; Rehabilitation; Sarcopenia.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Arthroplasty, Replacement, Hip
  • Biomarkers / blood
  • Exercise
  • Female
  • Hip Fractures / rehabilitation*
  • Hip Fractures / surgery
  • Humans
  • Male
  • Monitoring, Physiologic
  • Myostatin / blood*
  • Nutrition Assessment
  • Osteoporotic Fractures
  • Preliminary Data
  • Sarcopenia

Substances

  • Biomarkers
  • MSTN protein, human
  • Myostatin